DIGIFAB® Digoxin Immune Fab (Bovine)
BTG International Inc.
|Name||DIGIFAB® Digoxin Immune Fab (Bovine)|
|Description||DigiFab has an affinity for digoxin in the range of 109 to 1010 M-1, which is greater than the affinity of digoxin for its sodium pump receptor, the presumed receptor for its therapeutic and toxic effects. When administered to the intoxicated patient, DigiFab binds to molecules of digoxin reducing free digoxin levels, which results in a shift in the equilibrium away from binding to the receptors, thereby reducing cardio-toxic effects. Fab-digoxin complexes are then cleared by the kidney and reticuloendothelial system.|
|Active Ingredient||digoxin-immune ovine Fab (monovalent) immunoglobulin fragments|
|Indication||DigiFab is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although designed specifically to treat digoxin overdose, a product very similar to DigiFab (Digibind) has been used successfully to treat life-threatening digitoxin overdose. Since human experience is limited, and the consequences of repeated exposure are unknown, DigiFab is not indicated for milder cases of digitalis toxicity. Clinical conditions requiring administration of DigiFab include:
|Strengths||40 mg of digoxin immune Fab|